Literature DB >> 2121891

Widespread intradermal accumulation of mononuclear leukocytes in lepromatous leprosy patients treated systemically with recombinant interferon gamma.

C Nathan1, K Squires, W Griffo, W Levis, M Varghese, C K Job, A R Nusrat, S Sherwin, S Rappoport, E Sanchez.   

Abstract

Intradermal administration of recombinant interferon gamma (rIFN-gamma) to lepromatous leprosy patients has converted the local histology toward a tuberculoid pattern. However, such changes have been confined to the site of injection. In contrast, in the present study, marked, intradermal accumulation of CD3+, CD4+, CD8+, and CD1a+ T cells and Leu-M5+ mononuclear phagocytes was induced at a distance from the sites of administration, in a dose-dependent manner, by 10 daily intramuscular injections of 10-30 micrograms rIFN-gamma/m2. Mononuclear cell infiltration began within 3 d of onset of rIFN-gamma therapy and persisted at least 8 wk. Intramuscular administration of rIFN-gamma to lepromatous patients receiving concurrent chemotherapy can safely induce widespread histologic features of an upgrading reaction.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121891      PMCID: PMC2188674          DOI: 10.1084/jem.172.5.1509

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  7 in total

1.  Effects of intradermal gamma-interferon in cutaneous leishmaniasis.

Authors:  G Harms; K Zwingenberger; A K Chéhadé; S Talhari; P Racz; A Mouakeh; M Douba; L Näkel; R D Naiff; P G Kremsner
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

2.  Efficacy of a cell-mediated reaction to the purified protein derivative of tuberculin in the disposal of Mycobacterium leprae from human skin.

Authors:  G Kaplan; G Sheftel; C K Job; N K Mathur; I Nath; Z A Cohn
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

3.  Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy.

Authors:  C F Nathan; G Kaplan; W R Levis; A Nusrat; M D Witmer; S A Sherwin; C K Job; C R Horowitz; R M Steinman; Z A Cohn
Journal:  N Engl J Med       Date:  1986-07-03       Impact factor: 91.245

4.  Elimination of Mycobacterium leprae subsequent to local in vivo activation of macrophages in lepromatous leprosy by other mycobacteria.

Authors:  J Convit; M E Pinardi; G Rodríguez Ochoa; M Ulrich; J L Avila; M Goihman
Journal:  Clin Exp Immunol       Date:  1974-06       Impact factor: 4.330

5.  Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients.

Authors:  G Kaplan; A Nusrat; E N Sarno; C K Job; J McElrath; J A Porto; C F Nathan; Z A Cohn
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

6.  Effect of multiple interferon gamma injections on the disposal of Mycobacterium leprae.

Authors:  G Kaplan; N K Mathur; C K Job; I Nath; Z A Cohn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

7.  Reversal reactions in lepromatous leprosy following transfer factor therapy.

Authors:  R C Hastings; C K Job
Journal:  Am J Trop Med Hyg       Date:  1978-09       Impact factor: 2.345

  7 in total
  3 in total

1.  A journey in science: promise, purpose, privilege.

Authors:  Carl Nathan
Journal:  Mol Med       Date:  2013-10-03       Impact factor: 6.354

2.  A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin.

Authors:  Leanne M Johnson-Huang; Mayte Suárez-Fariñas; Katherine C Pierson; Judilyn Fuentes-Duculan; Inna Cueto; Tim Lentini; Mary Sullivan-Whalen; Patricia Gilleaudeau; James G Krueger; Asifa S Haider; Michelle A Lowes
Journal:  J Invest Dermatol       Date:  2012-01-26       Impact factor: 8.551

3.  Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients.

Authors:  E P Sampaio; A L Moreira; E N Sarno; A M Malta; G Kaplan
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.